No Need to Stop Estrogen in Transgender Women Before Gender-Affirming Surgery No Need to Stop Estrogen in Transgender Women Before Gender-Affirming Surgery
Transgender women can safely maintain their estrogen hormone therapy during gender-affirming surgery without an increased risk of venous thromboembolism (VTE), according to a new study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 20, 2021 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news
Estrogen Therapy Need Not Stop for Gender - Affirming Surgery
Authors find that perioperative venous thromboembolism rarely occurs, regardless of suspension of hormone therapy prior to surgery (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 19, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Surgery, Journal, Source Type: news
Estrogen Therapy Need Not Stop for Gender-Affirming Surgery
TUESDAY, Jan. 19, 2021 -- For transgender and gender nonbinary (TGNB) patients undergoing primary vaginoplasty, perioperative venous thromboembolism (VTE) occurs rarely, regardless of whether hormone therapy is suspended prior to surgery, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2021 Category: Pharmaceuticals Source Type: news
What Is Hormone Therapy Used For
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 12, 2021 Category: General Medicine Source Type: news
Sexual dysfunction hits some women harder than others as they age
(The North American Menopause Society (NAMS)) Sexual dysfunction often accompanies the menopause transition. Yet, not all women experience it the same. A new study identified the determinants that affect a woman's risk of sexual dysfunction and sought to determine the effectiveness of hormone therapy in decreasing that risk and modifying sexual behavior. Study results are published online in Menopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 6, 2021 Category: International Medicine & Public Health Source Type: news
With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs.
The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer.
Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs.
The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer.
Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news
With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs.
The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer.
Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs.
The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer.
Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news
New oral hormone drug for prostate cancer
The Food and Drug Administration has approved the use of a new oral hormone therapy drug, Relugolix, for treating advanced prostate cancer in men.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 22, 2020 Category: Endocrinology Source Type: news
FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer
MONDAY, Dec. 21, 2020 -- Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. Food and Drug Administration announced Friday.
As opposed to currently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news
FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer
Today, the FDA approved the first oral hormone therapy for treating advanced prostate cancer. This therapy may eliminate some patients ’ need to visit the clinic for treatments that require administration by a health care provider. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Transgender women retain athletic advantages after hormone therapy
Transgender women retain athletic advantages over cisgender women for 1-2 years after starting gender-affirming hormone therapy, according to a study published in theBritish Journal of Sports Medicine.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 17, 2020 Category: Endocrinology Source Type: news
Oral hormone therapy shown to significantly alter metabolome of menopausal women
(University of Massachusetts Amherst) Groundbreaking research led by a team of scientists including a University of Massachusetts Amherst biostatistician shows that oral hormone therapy (HT) significantly alters the metabolome of postmenopausal women. This finding, which examined blood specimens from the landmark Women's Health Initiative (WHI) study, may help explain the disease risks and protective effects associated with different regimens of hormone therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 16, 2020 Category: International Medicine & Public Health Source Type: news
